- Home
- DSGN vs ESPR Comparison
DSGN vs ESPR Comparison
Compare DSGN & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- ESPR
- Stock Information
- Founded
- DSGN 2017
- ESPR 2008
- Country
- DSGN United States
- ESPR United States
- Employees
- DSGN N/A
- ESPR N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- DSGN Health Care
- ESPR Health Care
- Exchange
- DSGN Nasdaq
- ESPR Nasdaq
- Market Cap
- DSGN 224.8M
- ESPR 208.1M
- IPO Year
- DSGN 2021
- ESPR 2013
- Fundamental
- Price
- DSGN $3.91
- ESPR $0.94
- Analyst Decision
- DSGN Hold
- ESPR Buy
- Analyst Count
- DSGN 1
- ESPR 7
- Target Price
- DSGN $4.00
- ESPR $5.93
- AVG Volume (30 Days)
- DSGN 91.9K
- ESPR 6.2M
- Earning Date
- DSGN 05-07-2025
- ESPR 05-06-2025
- Dividend Yield
- DSGN N/A
- ESPR N/A
- EPS Growth
- DSGN N/A
- ESPR N/A
- EPS
- DSGN N/A
- ESPR N/A
- Revenue
- DSGN N/A
- ESPR $259,574,000.00
- Revenue This Year
- DSGN N/A
- ESPR $4.07
- Revenue Next Year
- DSGN N/A
- ESPR N/A
- P/E Ratio
- DSGN N/A
- ESPR N/A
- Revenue Growth
- DSGN N/A
- ESPR 12.99
- 52 Week Low
- DSGN $2.60
- ESPR $0.69
- 52 Week High
- DSGN $7.77
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- DSGN 53.86
- ESPR 50.21
- Support Level
- DSGN $3.67
- ESPR $0.81
- Resistance Level
- DSGN $4.13
- ESPR $0.88
- Average True Range (ATR)
- DSGN 0.30
- ESPR 0.07
- MACD
- DSGN 0.05
- ESPR 0.02
- Stochastic Oscillator
- DSGN 85.78
- ESPR 95.43
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.